(New York, NY - May 2, 2019) -- Mount Sinai researchers have broken new ground in the understanding of the MDM2 gene--which is often overexpressed in cancer--finding that when it acts with a specific protein, it can lead to cancer cell death. The study appears in the May 2, 2019, print edition of Molecular Cell.
Their findings provide fresh insights into the cellular pathways that cause cancer, and may open new therapeutic opportunities for cancer treatment.
Cancer cells are known for altering the methods by which they consume and produce energy. The exact role and function of MDM2, the chronic expression of which is seen in cancer, was previously unclear to scientists. This was in part because MDM2 is characterized as both an oncogene--a mutated gene that has the capacity to transform normal cells into cancerous cells--as well as a tumor suppressor.
By studying human cancer cells, fruit flies, and genetically engineered mice, the researchers were able to show that when extra copies of the MDM2 gene occur in cancer, their presence disrupts cellular processes. Specifically, they found that MDM2 interacts with a protein found in cancer cells' mitochondria--the part of a cell that produces its energy, and thus its life--in a process that eventually promotes cancer cell death.
In addition, the team found that nutlin-3A, a promising therapy, enhanced the interaction between MDM2 and the mitochondrial protein, and thus would help kill cancer cells. This research also shows that MDM2 can be targeted in novel ways to promote its interaction with the mitochondrial protein in cancer cells to spur their death.
"Future research should involve delving into MDM2 biology and its pharmacological regulation and examining cellular respiration and mitochondrial dynamics. Understanding the exact nature of the cellular responses to MDM2-induced stress will help advance our efforts to develop concrete therapeutic treatments for cancer," explains lead investigator Jerry Chipuk, PhD, Associate Professor of Oncological Sciences, and Dermatology, and Associate Director for Basic Science Shared Resources at The Tisch Cancer Institute.
This work was supported by National Institutes of Health grants R01 CA157740, R01 CA206005 and R01 GM12995; the JJR Foundation; the William A. Spivak Fund; the Fridolin Charitable Trust; an American Cancer Society Research Scholar Award; a Leukemia & Lymphoma Society Career Development Award; and an Irma T. Hirschl/Monique Weill Caulier Trust Research Award. This work was also supported in part by two research grants (5FY1174 and 1FY13416) from the March of Dimes Foundation, the Developmental Research Pilot Project Program within the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, and the Tisch Cancer Institute Cancer Center Support Grant (P30 CA196521).
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.
For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.